Recombinant Spike glycoprotein (BTI-Tn-5B1-4)
Taxonomy : Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
SNFG, Text, Oxford
taxonomy (1)
protein (1)
source (1)
structure (0)
composition (66)
disease (1)
reference (2)
site (20)
peptide (108)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) P0DTC2
Protein
- BTI-Tn-5B1-4 (CVCL_C190)
Source
Reported structure
- HexNAc:1 (avg mass : 221.2103 )
- HexNAc:1 dHex:1 (avg mass : 367.3533 )
- HexNAc:1 dHex:2 (avg mass : 513.4963 )
- HexNAc:2 (avg mass : 424.4053 )
- HexNAc:2 dHex:1 (avg mass : 570.5483 )
- HexNAc:2 dHex:2 (avg mass : 716.6913 )
- Hex:1 HexNAc:2 (avg mass : 586.5477 )
- Hex:1 HexNAc:2 dHex:1 (avg mass : 732.6907 )
- Hex:1 HexNAc:2 dHex:2 (avg mass : 878.8337 )
- Hex:2 HexNAc:2 (avg mass : 748.6901 )
- Hex:2 HexNAc:2 dHex:1 (avg mass : 894.8331 )
- Hex:2 HexNAc:2 dHex:2 (avg mass : 1040.9761 )
- Hex:2 HexNAc:3 (avg mass : 951.8851 )
- Hex:2 HexNAc:3 dHex:1 (avg mass : 1098.0281 )
- Hex:2 HexNAc:3 dHex:2 (avg mass : 1244.1711 )
- Hex:2 HexNAc:5 (avg mass : 1358.2751 )
- Hex:3 HexNAc:2 (avg mass : 910.8325 )
- Hex:3 HexNAc:2 dHex:1 (avg mass : 1056.9755 )
- Hex:3 HexNAc:2 dHex:2 (avg mass : 1203.1185 )
- Hex:3 HexNAc:3 (avg mass : 1114.0275 )
- Hex:3 HexNAc:3 dHex:1 (avg mass : 1260.1705 )
- Hex:3 HexNAc:3 dHex:2 (avg mass : 1406.3135 )
- Hex:3 HexNAc:4 (avg mass : 1317.2225 )
- Hex:3 HexNAc:4 dHex:1 (avg mass : 1463.3655 )
- Hex:3 HexNAc:4 dHex:2 (avg mass : 1609.5085 )
- Hex:3 HexNAc:8 (avg mass : 2130.0025 )
- Hex:4 HexNAc:2 (avg mass : 1072.9749 )
- Hex:4 HexNAc:2 dHex:1 (avg mass : 1219.1179 )
- Hex:4 HexNAc:2 dHex:2 (avg mass : 1365.2609 )
- Hex:4 HexNAc:3 (avg mass : 1276.1699 )
- Hex:4 HexNAc:3 dHex:1 (avg mass : 1422.3129 )
- Hex:4 HexNAc:3 dHex:2 (avg mass : 1568.4559 )
- Hex:4 HexNAc:3 dHex:3 (avg mass : 1714.5989 )
- Hex:4 HexNAc:6 dHex:4 (avg mass : 2470.3269 )
- Hex:4 HexNAc:7 dHex:2 (avg mass : 2381.2359 )
- Hex:4 HexNAc:7 dHex:3 (avg mass : 2527.3789 )
- Hex:5 HexNAc:2 (avg mass : 1235.1173 )
- Hex:5 HexNAc:2 dHex:1 (avg mass : 1381.2603 )
- Hex:5 HexNAc:2 dHex:2 (avg mass : 1527.4033 )
- Hex:5 HexNAc:3 (avg mass : 1438.3123 )
- Hex:5 HexNAc:3 dHex:1 (avg mass : 1584.4553 )
- Hex:5 HexNAc:3 dHex:2 (avg mass : 1730.5983 )
- Hex:5 HexNAc:4 dHex:2 (avg mass : 1933.7933 )
- Hex:5 HexNAc:4 dHex:3 (avg mass : 2079.9363 )
- Hex:5 HexNAc:4 dHex:4 (avg mass : 2226.0793 )
- Hex:5 HexNAc:4 dHex:5 (avg mass : 2372.2223 )
- Hex:6 HexNAc:2 (avg mass : 1397.2597 )
- Hex:6 HexNAc:3 (avg mass : 1600.4547 )
- Hex:6 HexNAc:4 dHex:1 (avg mass : 1949.7927 )
- Hex:6 HexNAc:4 dHex:3 (avg mass : 2242.0787 )
- Hex:6 HexNAc:8 (avg mass : 2616.4297 )
- Hex:7 HexNAc:2 (avg mass : 1559.4021 )
- Hex:7 HexNAc:3 (avg mass : 1762.5971 )
- Hex:7 HexNAc:4 (avg mass : 1965.7921 )
- Hex:7 HexNAc:4 dHex:3 (avg mass : 2404.2211 )
- Hex:7 HexNAc:5 dHex:2 (avg mass : 2461.2731 )
- Hex:7 HexNAc:6 dHex:4 NeuAc:2 (avg mass : 3539.2699 )
- Hex:7 HexNAc:7 dHex:1 (avg mass : 2721.5201 )
- Hex:7 HexNAc:7 dHex:3 (avg mass : 3013.8061 )
- Hex:7 HexNAc:8 (avg mass : 2778.5721 )
- Hex:8 HexNAc:2 (avg mass : 1721.5445 )
- Hex:8 HexNAc:6 (avg mass : 2534.3245 )
- Hex:9 HexNAc:2 (avg mass : 1883.6869 )
- Hex:9 HexNAc:4 dHex:1 (avg mass : 2436.2199 )
- Hex:10 HexNAc:2 (avg mass : 2045.8293 )
- Hex:11 HexNAc:2 (avg mass : 2207.9717 )
Composition
- COVID-19 (DOID:0080600)
Disease
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
Reference
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
Reported glycosite
- SNVTWF (6aa)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- FHAIHVSGTNGTK (13aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- FQFCNDPFLGVYYHKNNKSWMESEF (25aa)
- VCEFQFCNDPFLGVYYHKNNKSWMESEFR (29aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEY (12aa)
- SSANNCTF (8aa)
- SSANNCTFEY (10aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- SEFRVYSSANNCTFEYVSQPFLMDLE (26aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VYSSANNCTFEYVSQPFLMDLEGKQGNFKNLR (32aa)
- VYSSANNCTF (10aa)
- VDLPIGINITR (11aa)
- PLVDLPIGINITR (13aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- NGTITDAVDCALDPLSETK (19aa)
- NGTITDAVDCALDPLSETKCTLK (23aa)
- TFLLKYNENGTITDAVDCALDPLSE (25aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPF (10aa)
- FPNITNL (7aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- GEVFNATRF (9aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VFNATR (6aa)
- FPNITNLCPFGEVFNATR (18aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- GGVSVITPGTNTSNQVAVL (19aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- DPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (57aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSY (14aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYE (7aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- SNNSIAIPTNF (11aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- KNFTTAPAICHDGK (14aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- GVFVSNGTHWFVTQR (15aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- KNHTSPDVDLGDISGINASVVNIQK (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQKEIDR (28aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- EIDRLNEVAKNLNESLIDLQELGK (24aa)
- LNEVAKNLNESLIDLQELGK (20aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- LNEVAKNLNESLIDLQELGKYEQYIK (26aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
Mass spectrometry observed peptide
-
- HexNAc:1 / N-Linked
(avg mass : 221.2103)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:1 dHex:1 / N-Linked
(avg mass : 367.3533)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- KNFTTAPAICHDGK (14aa)
- GVFVSNGTHWFVTQR (15aa)
- NFTTAPAICHDGK (13aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 / N-Linked
(avg mass : 424.4053)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:1 dHex:2 / N-Linked
(avg mass : 513.4963)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGEVFNATR (18aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 dHex:1 / N-Linked
(avg mass : 570.5483)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 / N-Linked
(avg mass : 586.5477)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EGVFVSNGTHW (11aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- NFTTAPAICHDGK (13aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 dHex:2 / N-Linked
(avg mass : 716.6913)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYE (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 dHex:1 / N-Linked
(avg mass : 732.6907)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHWFVTQR (16aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:2 / N-Linked
(avg mass : 748.6901)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- HAIHVSGTNGTK (12aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- NFSQILPDPSK (11aa)
- KNFTTAPAICHDGK (14aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- GVFVSNGTHWFVTQR (15aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 dHex:2 / N-Linked
(avg mass : 878.8337)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:2 dHex:1 / N-Linked
(avg mass : 894.8331)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- SNVTWF (6aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- FPNITNLCPF (10aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- VFNATR (6aa)
- FPNITNLCPFGEVFNATR (18aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- NFSQILPDPSK (11aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- HVTYVPAQEKNF (12aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VSNGTHW (7aa)
- EGVFVSNGTHWFVTQR (16aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 / N-Linked
(avg mass : 910.8325)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFEYVSQPFLMDLE (26aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPF (10aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVL (19aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- VPAQEKNF (8aa)
- HVTYVPAQEKNF (12aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- GVFVSNGTHWFVTQR (15aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:3 / N-Linked
(avg mass : 951.8851)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- IVNNATNVVIK (11aa)
-
- Hex:2 HexNAc:2 dHex:2 / N-Linked
(avg mass : 1040.9761)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPFGE (12aa)
- SIVRFPNITNLCPFGE (16aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VFNATR (6aa)
- FPNITNLCPFGEVFNATR (18aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHWFVTQR (16aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 dHex:1 / N-Linked
(avg mass : 1056.9755)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEY (12aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- SSANNCTFEY (10aa)
- VDLPIGINITR (11aa)
- PLVDLPIGINITR (13aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPF (10aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- VFNATR (6aa)
- FPNITNLCPFGEVFNATR (18aa)
- GEVFNATR (8aa)
- GEVFNATRF (9aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- AGCLIGAEHVNNSY (14aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- VPAQEKNF (8aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- HVTYVPAQEKNF (12aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
- EIDRLNEVAKNLNESLIDLQELGK (24aa)
-
- Hex:4 HexNAc:2 / N-Linked
(avg mass : 1072.9749)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTF (10aa)
- SSANNCTFEY (10aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- FPNITNLCPF (10aa)
- FPNITNL (7aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- NFSQILPDPSK (11aa)
- KNFTTAPAICHDGK (14aa)
- VPAQEKNF (8aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- GVFVSNGTHWFVTQR (15aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- NFTTAPAICHDGK (13aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:3 dHex:1 / N-Linked
(avg mass : 1098.0281)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- HAIHVSGTNGTK (12aa)
-
- Hex:3 HexNAc:3 / N-Linked
(avg mass : 1114.0275)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- SSANNCTFEY (10aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPF (10aa)
- FPNITNLCPFGE (12aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- VPAQEKNF (8aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- HVTYVPAQEKNF (12aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 dHex:2 / N-Linked
(avg mass : 1203.1185)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- FQFCNDPFLGVYYHKNNKSWMESEF (25aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- PLVDLPIGINITR (13aa)
- NGTITDAVDCALDPLSETK (19aa)
- NGTITDAVDCALDPLSETKCTLK (23aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VFNATR (6aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- GVFVSNGTHWFVTQR (15aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQKEIDR (28aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- LNEVAKNLNESLIDLQELGK (20aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- LNEVAKNLNESLIDLQELGKYEQYIK (26aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:4 HexNAc:2 dHex:1 / N-Linked
(avg mass : 1219.1179)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFEY (12aa)
- SEFRVYSSANNCTFE (15aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- KNFTTAPAICHDGK (14aa)
- VPAQEKNF (8aa)
- HVTYVPAQEKNF (12aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWFVTQR (16aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:5 HexNAc:2 / N-Linked
(avg mass : 1235.1173)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- FHAIHVSGTNGTK (13aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- HAIHVSGTNGTK (12aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- SSANNCTFEY (10aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- HVTYVPAQEKNF (12aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHWFVTQR (16aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:3 dHex:2 / N-Linked
(avg mass : 1244.1711)
- BTI-Tn-5B1-4 (CVCL_C190)
Source
- Hex:2 HexNAc:3 dHex:2 / N-Linked
(avg mass : 1244.1711)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:5 HexNAc:2 / N-Linked
(avg mass : 1235.1173)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:4 HexNAc:2 dHex:1 / N-Linked
(avg mass : 1219.1179)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- Hex:3 HexNAc:2 dHex:2 / N-Linked
(avg mass : 1203.1185)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:3 HexNAc:3 / N-Linked
(avg mass : 1114.0275)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- Hex:2 HexNAc:3 dHex:1 / N-Linked
(avg mass : 1098.0281)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:4 HexNAc:2 / N-Linked
(avg mass : 1072.9749)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:3 HexNAc:2 dHex:1 / N-Linked
(avg mass : 1056.9755)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- Hex:2 HexNAc:2 dHex:2 / N-Linked
(avg mass : 1040.9761)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- Hex:2 HexNAc:3 / N-Linked
(avg mass : 951.8851)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:3 HexNAc:2 / N-Linked
(avg mass : 910.8325)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:2 HexNAc:2 dHex:1 / N-Linked
(avg mass : 894.8331)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- Hex:1 HexNAc:2 dHex:2 / N-Linked
(avg mass : 878.8337)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:2 HexNAc:2 / N-Linked
(avg mass : 748.6901)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- Hex:1 HexNAc:2 dHex:1 / N-Linked
(avg mass : 732.6907)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- HexNAc:2 dHex:2 / N-Linked
(avg mass : 716.6913)
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
- Hex:1 HexNAc:2 / N-Linked
(avg mass : 586.5477)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- HexNAc:2 dHex:1 / N-Linked
(avg mass : 570.5483)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- HexNAc:1 dHex:2 / N-Linked
(avg mass : 513.4963)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- HexNAc:2 / N-Linked
(avg mass : 424.4053)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- HexNAc:1 dHex:1 / N-Linked
(avg mass : 367.3533)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
- HexNAc:1 / N-Linked
(avg mass : 221.2103)